Dr. Park was awarded a Fellowship of the Royal College of Physicians in 2009 and is also a Commissioner on Human Medicines and a Fellow of the Academy of Medical Sciences.
Dr. Park has received a number of honors and distinctions which include the B.P.S. Sandoz Prize for Pharmacology, the Pfizer Medal for Innovative Science, The SmithKline and Beecham Prize for Clinical Pharmacology, The Vane Prize for Drug Metabolism and The Werner Kalow Lectureship (Canada). He has authored over 400 peer-reviewed publications.
He currently leads the Innovative Medicines Initiative consortium in Europe, to evaluate existing and emerging models of how our liver responds to drugs, Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI).
“Drug induced liver injury is a major problem in the clinic and during drug development. DILI-sim will provide an in silico platform which will facilitate the discovery and design of new medicines that are both effective and safe.”